Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Hospitals Charging Private Insurers Nearly Four Times Acquisition Costs On Cancer Drugs – Study

Executive Summary

New report makes a case for further scrutiny of the 340B program's contributions to high drug costs, although manufacturers remain the main target of legislative and regulatory reform proposals.

You may also be interested in...



As Pricing Scrutiny Turns To Physician-Administered Drugs, PhRMA Points To Supply Chain Culprits

Hospital receive an average of 2.5 times what they pay for drugs in reimbursement from commercial payers, a white paper released by the trade group reports. And consolidation has increased the leverage hospitals wield in payment negotiations.

340B And US Drug Pricing: Trump’s First Target Is One That Lasts

The US government program that allows safety net providers to purchase drugs at deep discounts is probably not what most American voters have in mind when they say drug pricing is a top issue. But the 340B program has been a rare area of consistent focus – and actual sustained change – in the Trump Administration.

Pfizer Testing Warranty Offer With Xalkori, May Expand It To ‘Multiple’ Products

Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel